CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Moderna Inc. (MRNA) on Friday reported a loss of $1.12 billion in its fourth quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.91. Losses, adjusted for non-recurring costs, came to $2.50 per share.
The results topped Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for a loss of $2.69 per share.
The biotechnology company posted revenue of $966 million in the period, also beating Street forecasts. Nine analysts surveyed by Zacks expected $956.1 million.
Moderna expects full-year revenue in the range of $1.5 billion to $2.5 billion.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MRNA at https://www.zacks.com/ap/MRNA
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。